SFMPP Congress gave significant attention to the issue of pharmacogenetics.
This provided Boris Chaumette with an opportunity to reiterate that genomics will enable the development of precision psychiatry, supported by PEPR PROPSY program.
The identification of rare genetic diseases as part of the France Genomic Medicine 2025 Plan paves the way for a detailed understanding of pathophysiological mechanisms.
The implementation of pharmacokinetics allows for the personalization of prescribed doses and the prevention of serious side effects.
The program is available for consultation here.